results with those in the aforementioned study, we give the results for patients who were in clinically stable condition during the study period (eg, with no acute worsening in condition). 4 After exclusion of hospitalized patients, our population consisted of 21 men and 11 women with an average age of 66 years and average time of receiving dialysis of 33 months. The patients were divided into groups without (n = 15) and with (n = 17) a history of cardiovascular disease, which was considered present when the patient had a previous myocardial infarction, had required coronary intervention (eg, percutaneous transluminal coronary angioplasty or coronary artery bypass grafting), or had congestive cardiac failure. More details about the population can be found elsewhere. 4, 5 In ❚Figure 1❚, we summarize the NT-proBNP/BNP ratios measured during the 6-month study for each of the 32 patients (patients 16-32 have a history of cardiovascular disease). To clarify the results in Figure 1 and to foster understanding of the magnitude of the NT-proBNP/BNP ratios in this population, we mention that even patients with the lowest ratios, ie, patients 9, 12, and 13, had ratios of more than 5 on at least 1 occasion. It is interesting to note that although the withinpatient variations could be quite large, the median (interquartile ❚Figure 1❚ N-terminal-pro-Bnatriuretic peptide (NT-proBNP)/ BNP ratios measured during the 6-month follow-up period in 32 patients receiving hemodialysis (patients 16-32 have a history of cardiovascular disease).
range) NT-proBNP values did not change dramatically during the 6-month period and were 16.8 (7.6-25.0) at baseline, 12.7 (7.0-21.7) after 2 months, 14.0 (7.6-27.3) after 4 months, and 20.0 (9.01-26.5) after 6 months.
The values found in the dialysis population are, therefore, much higher than those found in patients with end-stage renal disease (chronic kidney disease stage 5) not receiving dialysis. Summarizing the preceding information seems to reveal that the relative amount of NT-proBNP (vs BNP) increases exponentially with a decrease in renal function and that this increase continues in patients receiving hemodialysis treatment. These findings are in agreement with those of Srisawasdi et al 1 and suggest large differences in the clearance or production of BNP and/or NT-proBNP in patients with chronic kidney disease. Future research is needed to identify the underlying mechanisms behind the strongly elevated 
The Authors' Reply
The letter by Jacobs et al broadens our study to include more patients with end-stage renal disease. Their results extend our observations into end-stage renal disease with hemodialysis. As we found, they observed an exponential relationship between the NT-proBNP/BNP ratio and renal disease stage.
In regard to the comments on the study by van Kimmenade et al 1 in which they observed only a slight linear relationship between the NT-proBNP/BNP ratio and the estimated glomerular filtration rate (eGFR), further reflection shows that the majority of their patients had an eGFR of more than 60 mL/min/1.73 m 2 , placing them at most in stage I or stage II. Thus, their results were weighted toward mildly affected renal function. The exponential change is observed with more severe renal disease. In fact, they commented that they observed an inverse correlation between the NT-proBNP/BNP ratio and the GFR at the lower extreme of renal function.
They noted, as well, that the concentrations of BNP and NT-proBNP are higher in patients with heart failure than in hypertensive patients for the same range of GFR. They concluded that in heart failure there is an increased secretion
